Cardiac safety profile of etamicastat, a novel peripheral selective dopamine- β-hydroxylase inhibitor in non-human primates, human young and elderly healthy volunteers and hypertensive patients

In conclusion, etamicastat is not likely to prolong the QT interval at therapeutic doses.
Source: IJC Metabolic and Endocrine - Category: Endocrinology Source Type: research